Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
以抗澱粉樣蛋白抗體爲基礎的埃克替尼治療阿爾茨海默病的廣泛標籤反映了監管機構對信懇智能的信任：分析師
On Tuesday, the FDA approved Eli Lilly and Co's (NYSE:LLY) Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer's disease.
FDA在週二批准了禮來（紐交所LLY）的Kisunla（donanemab）一月一次注射劑用於早期症狀性阿爾茨海默病成年人的靜脈輸液。
Once-monthly, Kisunla is the first and only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed, which can result in lower treatment costs and fewer infusions.
Kisunla是唯一具有支持在去除澱粉樣斑塊時停止治療的證據的澱粉樣斑塊靶向治療法，這可降低治療成本並減少輸液次數。
Also Read: Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
也可閱讀：爲什麼禮來（Eli Lilly）的股價在週二盤前上漲？
Amyloid is a protein produced naturally in the body that can clump together to create amyloid plaques. The excessive buildup of amyloid plaques in the brain may lead...
澱粉樣蛋白是身體自然產生的一種蛋白質，可以聚集在一起形成...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。